Hunan Fangsheng Pharmaceutical announced that its wholly-owned subsidiary, Jianmeng Pharmaceutical, has completed the long-term toxicity test for the blood-nourishing, wind-dispelling, and pain-relieving granules, and has submitted an application for market approval. On September 13, 2024, they received the acceptance notice.
方盛制药：全资子公司健盟药业养血祛风止痛颗粒获受理
Hunan Fangsheng Pharmaceutical: The wholly-owned subsidiary Jianmeng Pharmaceutical has received the acceptance of its application for the blood-nourishing, wind-dispelling, and pain-relieving granules.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated